Attia Attia1,2, Abdelrahman Ibrahim Abushouk3,4,5, Hussien Ahmed3,6,7, Mohamed Gadelkarim3,8, Ahmed Elgebaly3,9, Zeinab Hassan3,6,7, Mohamed M Abdel-Daim3,10, Ahmed Negida3,6,7. 1. Medical Research Group of Egypt, Cairo, Egypt. attiamohamed@azhar.edu.eg. 2. Faculty of Medicine, Al-Azhar University, Cairo, 31724, Egypt. attiamohamed@azhar.edu.eg. 3. Medical Research Group of Egypt, Cairo, Egypt. 4. Faculty of Medicine, Ain Shams University, Cairo, Egypt. 5. NovaMed Medical Research Association, Cairo, Egypt. 6. Faculty of Medicine, Zagazig University, El Shrakia, Egypt. 7. Student Research Unit, Zagazig University, El Shrakia, Egypt. 8. Faculty of Medicine, Alexandria University, Alexandria, Egypt. 9. Faculty of Medicine, Al-Azhar University, Cairo, 31724, Egypt. 10. Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
Abstract
BACKGROUND: Psoriasis is an inflammatory skin disease that affects 2-3% of the worldwide population. The interleukin-17 cytokine family has been proven to play a central role in the pathogenesis of psoriasis. Brodalumab is a novel biologic agent that targets interleukin-17 molecules and their receptors. We aimed to evaluate the safety and efficacy of brodalumab as a therapeutic agent for moderate-to-severe psoriasis in a meta-analysis framework. METHODS: A computer literature search of PubMed, OVID, Cochrane Central, EMBASE, EBSCO, Scopus, and Web of Science was conducted using relevant keywords. Data were extracted from eligible trials and analyzed using RevMan (Version 5.3 for windows) and OpenMeta [Analyst] software. RESULTS: Six clinical trials (n = 4118 patients) were pooled in the final analysis. The pooled effect size favored brodalumab over placebo in terms of the Psoriasis Area and Severity Index (PASI) 75 [risk ratio (RR) = 12.61, 95% confidence interval (CI) 9.74-16.34], PASI 90 (RR = 28.72, 95% CI 18.34-44.98), and PASI 100 (RR = 61.23, 95% CI 25.48-147.17). Analysis of secondary outcomes showed that brodalumab was superior to placebo in terms of static physician's global assessment (RR = 32.53, 95% CI 13.80-76.69) and psoriasis symptoms inventory scores (RR = 14.70, 95% CI 8.38-25.78). Meta-regression analysis found a significant linear association between the brodalumab dose and the effect size on PASI and psoriasis symptoms inventory scores. The rate of overall adverse events was slightly higher in the brodalumab group (RR = 1.13, 95% CI 1.06-1.22); however, none of the individual adverse events were significantly higher in the brodalumab group, compared to the placebo group. CONCLUSION: Brodalumab showed an acceptable safety profile and a robust efficacy in the treatment of moderate-to-severe plaque psoriasis. However, the current evidence is insufficient to confirm maintenance of these results in the long term; therefore, larger studies with longer follow-up periods are required.
BACKGROUND:Psoriasis is an inflammatory skin disease that affects 2-3% of the worldwide population. The interleukin-17 cytokine family has been proven to play a central role in the pathogenesis of psoriasis. Brodalumab is a novel biologic agent that targets interleukin-17 molecules and their receptors. We aimed to evaluate the safety and efficacy of brodalumab as a therapeutic agent for moderate-to-severe psoriasis in a meta-analysis framework. METHODS: A computer literature search of PubMed, OVID, Cochrane Central, EMBASE, EBSCO, Scopus, and Web of Science was conducted using relevant keywords. Data were extracted from eligible trials and analyzed using RevMan (Version 5.3 for windows) and OpenMeta [Analyst] software. RESULTS: Six clinical trials (n = 4118 patients) were pooled in the final analysis. The pooled effect size favored brodalumab over placebo in terms of the Psoriasis Area and Severity Index (PASI) 75 [risk ratio (RR) = 12.61, 95% confidence interval (CI) 9.74-16.34], PASI 90 (RR = 28.72, 95% CI 18.34-44.98), and PASI 100 (RR = 61.23, 95% CI 25.48-147.17). Analysis of secondary outcomes showed that brodalumab was superior to placebo in terms of static physician's global assessment (RR = 32.53, 95% CI 13.80-76.69) and psoriasis symptoms inventory scores (RR = 14.70, 95% CI 8.38-25.78). Meta-regression analysis found a significant linear association between the brodalumab dose and the effect size on PASI and psoriasis symptoms inventory scores. The rate of overall adverse events was slightly higher in the brodalumab group (RR = 1.13, 95% CI 1.06-1.22); however, none of the individual adverse events were significantly higher in the brodalumab group, compared to the placebo group. CONCLUSION:Brodalumab showed an acceptable safety profile and a robust efficacy in the treatment of moderate-to-severe plaque psoriasis. However, the current evidence is insufficient to confirm maintenance of these results in the long term; therefore, larger studies with longer follow-up periods are required.
Authors: Kim A Papp; Cathy Reid; Peter Foley; Rod Sinclair; David H Salinger; Gary Williams; Hua Dong; James G Krueger; Chris B Russell; David A Martin Journal: J Invest Dermatol Date: 2012-05-24 Impact factor: 8.551
Authors: Emily Smith; Matthew A Stark; Alexander Zarbock; Tracy L Burcin; Anthony C Bruce; Devin Vaswani; Patricia Foley; Klaus Ley Journal: J Immunol Date: 2008-07-15 Impact factor: 5.422
Authors: Theresa N Canavan; Craig A Elmets; Wendy L Cantrell; John M Evans; Boni E Elewski Journal: Am J Clin Dermatol Date: 2016-02 Impact factor: 7.403
Authors: Mark C Genovese; Maria Greenwald; Chul-Soo Cho; Alberto Berman; Ling Jin; Gregory S Cameron; Olivier Benichou; Li Xie; Daniel Braun; Pierre-Yves Berclaz; Subhashis Banerjee Journal: Arthritis Rheumatol Date: 2014-07 Impact factor: 10.995
Authors: Ryan Rivera-Oyola; Roselyn Stanger; Graham H Litchman; Quinn Thibodeaux; John Koo; Richard Fried; Gary Goldenberg; George Han; Sylvia Hsu; Leon Kircik; Melissa Knuckles; Andrea Murina; Jeffrey Weinberg; Jashin J Wu; Mark Lebwohl Journal: J Clin Aesthet Dermatol Date: 2020-12-01
Authors: Xiang Li; Marie Anderson; Delphine Collin; Ingo Muegge; John Wan; Debra Brennan; Stanley Kugler; Donna Terenzio; Charles Kennedy; Siqi Lin; Mark E Labadia; Brian Cook; Robert Hughes; Neil A Farrow Journal: J Biol Chem Date: 2017-05-25 Impact factor: 5.157
Authors: Diana Brixner; Gary Oderda; Joseph Biskupiak; Douglas S Burgoyne; Steven G Avey; Steven R Feldman Journal: Am Health Drug Benefits Date: 2019-02
Authors: Femke A Meijer; Richard G Doveston; Rens M J M de Vries; Gaël M Vos; Alex A A Vos; Seppe Leysen; Marcel Scheepstra; Christian Ottmann; Lech-Gustav Milroy; Luc Brunsveld Journal: J Med Chem Date: 2019-12-24 Impact factor: 7.446